Bryn Mawr Trust CO Larimar Therapeutics, Inc. Transaction History
Bryn Mawr Trust CO
- $5.88 Billion
- Q3 2025
A detailed history of Bryn Mawr Trust CO transactions in Larimar Therapeutics, Inc. stock. As of the latest transaction made, Bryn Mawr Trust CO holds 455 shares of LRMR stock, worth $1,769. This represents 0.0% of its overall portfolio holdings.
Number of Shares
455Holding current value
$1,769% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding LRMR
# of Institutions
130Shares Held
66.9MCall Options Held
4.83MPut Options Held
83.7K-
Deerfield Management Company, L.P. (Series C) New York, NY21.2MShares$82.6 Million1.41% of portfolio
-
Ra Capital Management, L.P. Boston, MA6.05MShares$23.5 Million0.38% of portfolio
-
Blue Owl Capital Holdings LP New York, NY4.93MShares$19.2 Million7.71% of portfolio
-
Opaleye Management Inc. Boston, MA4.11MShares$16 Million2.84% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny3.66MShares$14.2 Million0.01% of portfolio
About Larimar Therapeutics, Inc.
- Ticker LRMR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 43,269,200
- Market Cap $168M
- Description
- Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. T...